PepGen remains in a high-risk, pre-revenue clinical development phase, with its valuation heavily dependent on the success of its EDO platform. The company faces significant capital intensity, as evidenced by quarterly R&D expenditures that reached $25.4 milli...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.26+8.6% vs -$0.28 | — vs — |
Q2 2026 May 12, 2026 | -$0.26+16.1% vs -$0.31 | — vs — |
Q2 2026 Mar 4, 2026 | -$0.27+32.5% vs -$0.40 | — vs — |
Q4 2025 Nov 12, 2025 | -$0.52+17.5% vs -$0.63 | — vs — |
Squarepoint Ops LLC raised its holdings in PepGen, Inc. (NASDAQ: PEPG) by 260.9% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 529,083 shares of the company's stock after purchasing an additional 382,487 shares during the period. Squarepoint
ADAR1 Capital Management LLC acquired a new position in PepGen, Inc. (NASDAQ: PEPG) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 2,591,085 shares of the company's stock, valued at approximately $4,664,000. ADAR1 Capital Management LLC owned approximately 3.74% of PepGen as of
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the
[url="]PepGen Inc.[/url] (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of tran
Benchmark PEPG against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for PepGen Inc. (PEPG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.72 | $188.14M | -1.28 | — | — | -67.39% | — | |
| $18.95 | $2B | -2.66 | 15.58% | -6.93% | -9.96% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $14.88 | $1.47B | -2.55 | 20.13% | -81.79% | — | — | |
| $55.76 | $5.38B | -8.62 | -89.97% | -3368.72% | -24.39% | — | |
| $2.69 | $412.81M | -1.49 | 25.39% | -157.32% | -196.63% | — |
PepGen Inc. (PEPG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
PepGen Inc. (PEPG) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 22, 2026·SEC
May 21, 2026·SEC
Get notified when PEPG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PepGen Inc. (PEPG) stock FAQ — growth, dividends, profitability & financials explained
PepGen Inc. (PEPG) reported a net loss of $71.9M for fiscal year 2025.
PepGen Inc. (PEPG) has a return on equity (ROE) of -67.4%. Negative ROE indicates the company is unprofitable.
PepGen Inc. (PEPG) had negative free cash flow of $69.5M in fiscal year 2025, likely due to heavy capital investments.
